NCT01495013 - A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

427

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

September 30, 2013

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

1mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

2mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

3mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

4mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

1mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

2mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

3mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

4mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

1mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

2mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

3mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

4mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

10mg Atorvastatin

1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily

DRUG

20mg Atorvastatin

1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily

Trial Locations (33)

1008

GSK Investigational Site, Manila

1012

GSK Investigational Site, Santa Cruz, Manila

1600

GSK Investigational Site, Pasig

6000

GSK Investigational Site, Cebu City

8000

GSK Investigational Site, Davao City

10400

GSK Investigational Site, Rajathevee

11650

GSK Investigational Site, Mexico City

16150

GSK Investigational Site, Kubang Kerian

30000

GSK Investigational Site, Nakhon Ratchasima

30450

GSK Investigational Site, Ipoh

57000

GSK Investigational Site, Chiangrai

59100

GSK Investigational Site, Kuala Lumpur

62250

GSK Investigational Site, Cuernavaca

80100

GSK Investigational Site, Johor Bahru

109240

GSK Investigational Site, Moscow

191119

GSK Investigational Site, Saint Petersburg

410054

GSK Investigational Site, Saratov

463442

GSK Investigational Site, Suwon

06700

GSK Investigational Site, Del. Cuauhtémoc

GSK Investigational Site, Mexico City

C.P. 44130

GSK Investigational Site, Gadalajara, Jalisco

C.P. 44210

GSK Investigational Site, Guadalajara Jalisco

134 727

GSK Investigational Site, Bucheon-si

602-739

GSK Investigational Site, Busan

220-701

GSK Investigational Site, Kangwondo

137-701

GSK Investigational Site, Seocho-ku, Seoul